Treating PsO with adalimumab and concomitant methotrexate has no difference in effectiveness and persistence when compared to adalimumab monotherapy.

PsO patients with low BSA involvement may experience similar QoL and disease burden as patients with high BSA.

Guselkumab is effective in treating moderate-to-severe scalp psoriasis in patients with Fitzpatrick Skin Types IV through VI.

Patients with GPP have a five times higher risk of all-cause mortality at one year than those without GPP.

Biologic treatment of psoriasis can raise the risk of superficial fungal infections in patients, especially with IL-17 inhibitors.

More than one-third of psoriasis patients on biologics still have increased inflammatory markers in their blood.

Psoriasis patients with intermediate skin phenotypes and a history of phototherapy had a higher risk of excessive sun exposure.

Female psoriasis patients have shorter drug survival for biologics compared to men.